umu.sePublications
Change search
Link to record
Permanent link

Direct link
BETA
Lizana, Helena
Publications (3 of 3) Show all publications
Lizana, H., Johansson, L., Axelsson, J., Larsson, A., Ögren, M., Linder, J., . . . Jakobson Mo, S. (2018). Whole-Body Biodistribution and Dosimetry of the Dopamine Transporter Radioligand 18F-FE-PE2I in Human Subjects. Journal of Nuclear Medicine, 59(8), 1275-1280
Open this publication in new window or tab >>Whole-Body Biodistribution and Dosimetry of the Dopamine Transporter Radioligand 18F-FE-PE2I in Human Subjects
Show others...
2018 (English)In: Journal of Nuclear Medicine, ISSN 0161-5505, E-ISSN 1535-5667, Vol. 59, no 8, p. 1275-1280Article in journal (Refereed) Published
Abstract [en]

F-18-(E)-N-(3-iodoprop-2-enyl)-2 beta-carbofluoroethoxy-3 beta-(4'-methylphenyl) nortropane (F-18-FE-PE2I) was recently developed and has shown adequate affinity and high selectivity for the dopamine transporter (DAT). Previous studies have shown promising results for F-18-FE-PE2I as a suitable radioligand for DAT imaging. In this study, we investigated the whole-body biodistribution and dosimetry of F-18-FE-PE2I in healthy volunteers to support its utility as a suitable PET imaging agent for the DAT. Methods: Five healthy volunteers were given a mean activity of 2.5 MBq/kg, and 3 PET scans, head to thigh, were performed immediately after injection followed by 4 whole-body PET/CT scans between 0.5 and 6 h after injection. Blood samples were drawn in connection with the whole-body scans, and all urine was collected until 6 h after injection. Volumes of interest were delineated around 17 organs on all images, and the areas under the time-activity curves were calculated to obtain the total number of decays in the organs. The absorbed doses to organs and the effective dose were calculated using the software IDAC. Results: The highest activity concentration was observed in the liver (0.9%-1.2% injected activity/100 g) up to 30 min after injection. At later time points, the highest concentration was seen in the gallbladder (1.1%-0.1% injected activity/100 g). The activity excreted with urine ranged between 23% and 34%, with a mean of 28%. The urinary bladder received the highest absorbed dose (119 mu Gy/MBq), followed by the liver (46 mu Gy/MBq). The effective dose was 23 mu Sv/MBq (range, 19-28 mu Sv/MBq), resulting in an effective dose of 4.6 mSv for an administered activity of 200 MBq. Conclusion: The effective dose is within the same order of magnitude as other commonly used PET imaging agents as well as DAT agents. The reasonable effective dose, together with the previously reported favorable characteristics for DAT imaging and quantification, indicates that F-18-FE-PE2I is a suitable radioligand for DAT imaging.

Keywords
F-18-FE-PE2I, dosimetry, biodistribution, DAT, effective dose
National Category
Radiology, Nuclear Medicine and Medical Imaging
Identifiers
urn:nbn:se:umu:diva-150823 (URN)10.2967/jnumed.117.197186 (DOI)000440582000020 ()29348315 (PubMedID)
Available from: 2018-08-21 Created: 2018-08-21 Last updated: 2018-08-21Bibliographically approved
Lizana, H., Johansson, L., Larsson, A., Axelsson, J., Linder, J., Ögren, M., . . . Jakobson Mo, S. (2016). Dosimetry and whole body distribution of [F-18]PE2I in healthy volunteers. Paper presented at Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Barcelona, SPAIN, OCT 15-19, 2016. European Journal of Nuclear Medicine and Molecular Imaging, 43, S533-S533
Open this publication in new window or tab >>Dosimetry and whole body distribution of [F-18]PE2I in healthy volunteers
Show others...
2016 (English)In: European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, E-ISSN 1619-7089, Vol. 43, p. S533-S533Article in journal, Meeting abstract (Refereed) Published
National Category
Radiology, Nuclear Medicine and Medical Imaging
Identifiers
urn:nbn:se:umu:diva-131670 (URN)10.1007/s00259-016-3484-4 (DOI)000391802500093 ()
Conference
Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Barcelona, SPAIN, OCT 15-19, 2016
Note

Supplement: 1, Meeting Abstract: EP827

Available from: 2017-02-23 Created: 2017-02-23 Last updated: 2018-06-09Bibliographically approved
Sydoff, M., Lizana, H., Mattsson, S., Stabin, M. G. & Leide-Svegborn, S. (2013). Determination of the biodistribution and dosimetry of I-123-FP-CIT in male patients with suspected Parkinsonism or Lewy body dementia using planar and combined planar and SPECT/CT imaging. Applied Radiation and Isotopes, 82, 300-307
Open this publication in new window or tab >>Determination of the biodistribution and dosimetry of I-123-FP-CIT in male patients with suspected Parkinsonism or Lewy body dementia using planar and combined planar and SPECT/CT imaging
Show others...
2013 (English)In: Applied Radiation and Isotopes, ISSN 0969-8043, E-ISSN 1872-9800, Vol. 82, p. 300-307Article in journal (Refereed) Published
Abstract [en]

In this study, I-123-FP-CIT biodistribution and dosimetry was determined in 10 adult male patients using planar gamma camera imaging alone or in combination with single photon emission computed tomography /X-ray computed tomography (SPECT/CT) imaging. Dosimetric assessment using planar plus SPECT/CT imaging resulted in significantly different estimates of organ-absorbed doses compared to estimates based on planar imaging alone. We conclude that the use of complementary SPECT/CT measurements in biodistribution studies is valuable for determining the organ doses more accurately.

Place, publisher, year, edition, pages
Elsevier, 2013
Keywords
Biokinetics, Dosimetry, I-123-FP-CIT, Lewy body dementia, Parkinson's disease
National Category
Radiology, Nuclear Medicine and Medical Imaging
Identifiers
urn:nbn:se:umu:diva-85635 (URN)10.1016/j.apradiso.2013.09.006 (DOI)000328804000046 ()
Funder
EU, FP7, Seventh Framework Programme, FP7-212100Swedish Radiation Safety Authority, SSM 2009/3400, 1586-01
Available from: 2014-02-10 Created: 2014-02-07 Last updated: 2018-06-08Bibliographically approved
Organisations

Search in DiVA

Show all publications